Helius Medical Technologies, Inc. Announces Q3 2023 Financial Results and Extended Cash Runway
Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on therapeutic neuromodulation for balance and gait deficits, has announced the release of its third quarter 2023 financial results on November 9, 2023. The company expects to report Q3 revenues in the range of $140,000 to $150,000, reflecting the conclusion of the Patient Therapy Access Program (PTAP) on June 30, 2023. Additionally, Helius anticipates approximately $7.0 million in cash, cash equivalents, and proceeds receivable from warrant exercises, extending its cash runway into Q2 2024. The company has maintained a focus on cash management, with cash used in operating activities for the first nine months of 2023 ranging from $8.3 million to $8.4 million, and for Q3 $2.4 million to $2.5 million.
Helius Medical Technologies will host a conference call to discuss the financial results and provide an expanded business update on the U.S. commercialization of PoNS®. The call will be hosted by Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer.
In conclusion, Helius Medical Technologies' announcement of its Q3 2023 financial results and extended cash runway highlights the company's financial performance and strategic plans.
Hot Take: Impact of Financial Results and Cash Runway on New Businesses
Helius Medical Technologies' recent announcement of its Q3 2023 financial results and extended cash runway provides a valuable lesson for new businesses. The company's focus on cash management and its ability to extend its cash runway into Q2 2024 highlights the importance of financial sustainability in business success.
Financial Sustainability
Helius' financial results reflect its ability to generate revenue and manage its cash flow effectively, two crucial aspects for any business. For new businesses, this serves as a reminder that financial sustainability is a key factor in long-term survival and growth.
Cash Runway
The extension of Helius' cash runway into Q2 2024 demonstrates the company's strategic planning and financial management. For new businesses, understanding and managing their cash runway is vital to ensure they have sufficient funds to cover their operational costs and invest in growth opportunities.
Strategic Planning
Helius' decision to host a conference call to discuss its financial results and provide an expanded business update shows the company's commitment to transparency and strategic planning. For new businesses, this highlights the importance of clear communication with stakeholders and strategic planning for future growth.
In conclusion, Helius Medical Technologies' financial results and extended cash runway provide important insights for new businesses on financial sustainability, cash management, and strategic planning.
.svg)
